Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

CVS HEALTH (CVS)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

CVS Health : Public Health and CVS Health Make Overdose-Reversal Drug Available Without Individual Prescription at CVS Pharmacy Locations in Delaware

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 02:30pm CET

DOVER, Del., Nov. 10 -- The Delaware Department of Health and Social Services issued the following news release:

The Delaware Division of Public Health and CVS Health announced today that the opioid overdose-reversal medication naloxone is now available without an individual prescription at all of the 20 CVS Pharmacy locations in Delaware, including those located inside Target stores. CVS pharmacists will be able to dispense naloxone to patients without an individual prescription under a statewide standing order issued by the Division of Public Health (DPH).

"By making naloxone available to the public without a prescription, CVS Health has taken an important step in helping us combat the opioid epidemic here in Delaware," said Governor John Carney. "Naloxone can give people a second chance to get medical care and be connected to resources to treat their addiction. We greatly appreciate their partnership."

"Naloxone is a safe and effective antidote to opioid overdoses and by expanding access to this medication in our pharmacies in Delaware we can help save lives," said Tom Davis, RPh, Vice President of Pharmacy Professional Services at CVS Pharmacy. "CVS Health is dedicated to helping the communities we serve address and prevent prescription drug abuse and we are expanding access to naloxone to give more people a chance to get the help they need for recovery."

In July, Governor Carney signed Senate Bill 48, which expanded community access to naloxone by ensuring pharmacists had the same legal protections as doctors, peace officers and good Samaritans. Pharmacists can now dispense the medicine responsibly without potential legal, criminal, or disciplinary actions due to injuries or death sustained in connection with dispensing the drug. Naloxone will be available at the pharmacy counter in participating pharmacies to anyone who is educated on its appropriate use and signs an acknowledgement form. DPH hopes that this measure, in combination with a revised standing order allowing pharmacists to dispense naloxone nasal spray, will increase access for those concerned about someone at risk of an overdose.

"Our first priority is to save lives, and expanding access to this overdose-reversing medication through local pharmacies gives more people in the community the opportunity to help us do that," said Dr. Rattay. "We see no signs of the opioid epidemic slowing and we need all the tools at our disposal to turn the tide."

Overdose deaths in Delaware climbed from 172 in 2012 to 228 in 2015, and then jumped to 308 deaths in 2016. There have been approximately 190 suspected drug overdose deaths to date in 2017. First responders administered the life-saving medication naloxone more than 1,535 times in 2016 and 1,280 times in the first half of 2017.

"Addiction is a chronic disease," said Dr. Kara Odom Walker, Secretary of the Delaware Department of Health and Social Services (DHSS). "As we expand access, we also need to connect Delawareans suffering from addiction to comprehensive and person-centered treatment services so they can begin their recovery."

For more information about how to access naloxone at the pharmacy and to receive training on how to use it, visit HelpisHereDE.com/Get-Help/Overdose-Response. HelpIsHere.com is DHSS' one-stop clearinghouse website for information on prevention, treatment and recovery resources in Delaware, and learning about the signs of addiction.

Within three to five minutes after administration, naloxone can counteract the life-threatening respiratory depression of an opioid-related overdose and stabilize a person's breathing, which buys time for emergency medical help to arrive. DPH recommends calling 9-1-1 immediately if you find someone in the midst of a suspected overdose, starting rescue breathing, and then administering naloxone. Naloxone is not a replacement for emergency medical care and seeking immediate help and follow-up care is still vital.

" 'If we had a 911 Good Samaritan law or Narcan law, your son might very well be alive today.' Those were the words of the detective investigating my son, Greg's, accidental heroin overdose," said David Humes, board member of atTAcK addiction. "I've lived with those words every day for over five years. With naloxone now being made available over-the-counter, other loved ones won't have to live with those words. Greater access to naloxone means more lives will be saved. More people will get a second chance."

For a list of permanent drug collection sites to safely dispose of unused prescription medication, visit permanent collection sites, visit DPH at http://dhss.delaware.gov/dph/hsp/hhdrugtakeback.html.

A person who is deaf, hard-of-hearing, deaf-blind or speech-disabled can call the DPH phone number above by using TTY services. Dial 7-1-1 or 800-232-5460 to type your conversation to a relay operator, who reads your conversation to a hearing person at DPH. The relay operator types the hearing person's spoken words back to the TTY user. To learn more about TTY availability in Delaware, visit http://delawarerelay.com.

Delaware Health and Social Services is committed to improving the quality of the lives of Delaware's citizens by promoting health and well-being, fostering self-sufficiency, and protecting vulnerable populations. DPH, a division of DHSS, urges Delawareans to make healthier choices with the 5-2-1 Almost None campaign: eat 5 or more fruits and vegetables each day, have no more than 2 hours of recreational screen time each day (includes TV, computer, gaming), get 1 or more hours of physical activity each day, and drink almost no sugary beverages.

Delaware Health and Social Services is committed to improving the quality of the lives of Delaware's citizens by promoting health and well-being, fostering self-sufficiency, and protecting vulnerable populations.

This document was posted showing the date: Nov. 9, 2017.

Targeted News Service, source News Service

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH
01/19 Delaware sues opioid manufacturers, distributors over epidemic
01/19 CVS HEALTH : FORTUNE Recognizes CVS Health on 2018 List of "World's Most Admired..
01/19 CVS HEALTH : FORTUNE® Recognizes CVS Health on 2018 List of "World's Most Admire..
01/18 AETNA : Shareholder Sues To Block CVS Deal
01/17 CVS HEALTH : Launches New Transform Rheumatoid Arthritis Care Program to Improve..
01/17 CVS HEALTH : Launches New Transform Rheumatoid Arthritis Care™ Program to ..
01/16 CVS ADDS 42 DRUG DISPOSAL BOXES ACRO : Here's where you can drop off unwanted me..
01/16 CVS HEALTH : opening drug disposal units in 40 locations, including 2 in Greater..
01/16 CVS HEALTH : to stop touchups in ads
01/15 CVS HEALTH : says it will no longer touch up photos used in marketing of beauty ..
More news
News from SeekingAlpha
01/20 Invest In Walgreens Or CVS, Speculate In Rite Aid
01/18 CVS Health Reminds Us That Investing Is 90% Half Common Sense
01/18 BY THE NUMBERS : Hunting For Undervalued Stocks
01/18 11 Upcoming Dividends Including 2 Kings
01/18 10 Dividend Growth Stocks For January 2018
Financials ($)
Sales 2017 184 B
EBIT 2017 9 944 M
Net income 2017 5 216 M
Debt 2017 24 376 M
Yield 2017 2,49%
P/E ratio 2017 15,94
P/E ratio 2018 14,13
EV / Sales 2017 0,57x
EV / Sales 2018 0,54x
Capitalization 80 898 M
Chart CVS HEALTH
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 88,0 $
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH10.15%80 898
WALGREENS BOOTS ALLIANCE4.35%75 733
EXPRESS SCRIPTS HOLDING CO7.18%45 434
MCKESSON CORPORATION10.82%35 516
CARDINAL HEALTH18.57%22 667
AMERISOURCEBERGEN10.32%21 821